Biomx Inc
AMEX:PHGE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Biomx Inc
Other Long-Term Assets
Biomx Inc
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Biomx Inc
AMEX:PHGE
|
Other Long-Term Assets
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Other Long-Term Assets
$1.4m
|
CAGR 3-Years
-79%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
30%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Other Long-Term Assets
$582.9m
|
CAGR 3-Years
1 024%
|
CAGR 5-Years
466%
|
CAGR 10-Years
168%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Other Long-Term Assets
$5.3m
|
CAGR 3-Years
21%
|
CAGR 5-Years
78%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Other Long-Term Assets
$96k
|
CAGR 3-Years
24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Other Long-Term Assets
$2.7m
|
CAGR 3-Years
29%
|
CAGR 5-Years
30%
|
CAGR 10-Years
14%
|
|
Biomx Inc
Glance View
BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. The firm is focused on developing both natural and engineered phage therapies. The company develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The firm discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
See Also
What is Biomx Inc's Other Long-Term Assets?
Other Long-Term Assets
0
USD
Based on the financial report for Dec 31, 2025, Biomx Inc's Other Long-Term Assets amounts to 0 USD.
